| Document |
Document Title |
|
WO/2020/221145A1 |
Disclosed is a method for preparing a pearl shell whitening factor, comprising the following steps of: clam shell crushing and sieving; performing mixing with a weak acid aqueous solution, stirring for decomposition, and a solid being se...
|
|
WO/2020/223581A1 |
A poly-N-substituted glycine compound of a formula A-(X-Y-Z)n-B is provided, wherein A is a terminal N-alkyl substituted glycine residue; n is an integer; B is selected from the group consisting of NH2, one and two N-substituted glycine ...
|
|
WO/2020/158811A1 |
One purpose of the present invention is to provide a simple method for detecting H. pylori and simultaneously obtaining information related to the genotype of CagA protein of H. pylori. This method for detecting H. pylori includes: (i) a...
|
|
WO/2019/183265A9 |
The presently disclosed subject matter relates to peptides and flavor compositions that include at least one, two, three, four, five or more peptide compounds, and screening methods for identifying the same. The flavor compositions can b...
|
|
WO/2020/085219A1 |
Provided is a method for selecting a mineral containing arsenic. A peptide having the following amino acid sequence: (TSNQ)-(LIVFA)-(ED)-(RKNMDCPQSETGWHY)-(LIVFA)-(RKNMDCPQSETGW
HY)-(LIVFA)-(LIVFA)-(LIVFA)-(RHK)-(TSNQ)-(TSNQ) [wherein an...
|
|
WO/2020/077136A1 |
Charged polypeptides, their conjugates, and fusion proteins comprising such polypeptides are disclosed. Inclusion of such a polypeptide in a fusion protein increases the protein's properties such as stability and circulation half-life, w...
|
|
WO/2020/065595A1 |
The present invention relates to synthetic leopeptides of formula Cn-X1-X2-X3-NH2 , wherein: Cn is a fatty acid selected from the group consisting of C12 to C16; X1 is at least one glycine molecule; X2 is at least two natural amino acids...
|
|
WO/2020/067400A1 |
Provided are: an immune inducer that comprises, as an active ingredient, a polynucleotide/peptide conjugate wherein a CpG motif-containing single-stranded polynucleotide or polynucleotide derivative is bonded to a peptide having antigeni...
|
|
WO/2020/023670A1 |
Provided are peptides, modified peptides, fragments thereof, conjugates thereof, and polymers thereof that have antibacterial activity against bacterial that include but are not limited to multidrug-resistant bacteria. In some embodiment...
|
|
WO/2020/013265A1 |
The purpose of the present invention is to provide a technology which is for promoting the permeation of drugs through a membrane and which has high versatility and higher safety. Said purpose can be achieved by this polymer compound hav...
|
|
WO/2020/008403A1 |
The present invention relates to an isolated peptide suitable as standard for the assaying of proAKAP4. Typically, said peptide is selected among the peptides having an N-terminus made of a region that is 100% identical to a region of th...
|
|
WO/2020/005120A1 |
The invention is directed to new enzymes of fungal luciferin biosynthesis, the nucleic acids that encode them, and the use of proteins as enzymes catalyzing the stages of fungal luciferin biosynthesis. The invention also provides the use...
|
|
WO/2019/245938A1 |
The present invention relates to, inter alia, compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment of disease, such as microbiome-related diseases. In part, the invention provides, in vario...
|
|
WO/2019/240288A1 |
The present invention provides art that enables modification of an antibody, particularly regioselective modification of an antibody. More specifically, the present invention provides a substance having affinity for an antibody, and a co...
|
|
WO/2019/219979A1 |
Described herein are a γ chain or a δ chain of a yδ5TCR or a yδ5TCR or a fragment thereof or a a nucleic acid molecule encoding them, a cell comprising preferably expressing them and their therapeutic uses for treating cancer in a su...
|
|
WO/2019/204663A1 |
The present disclosure relates to compositions comprising a peptide with improved solubility and the methods of achieving the same. In one embodiment, the present composition comprises at least one peptide, a pH modifier present at a con...
|
|
WO/2019/166347A1 |
The present invention relates to a family of peptides which are able to interfere in the formation of complex Munc18-Syntaxin-1 and, hence, are useful in the prevention and/or treatment of neuronal exocytosis and/or muscle contractility ...
|
|
WO/2019/169145A1 |
This document provides materials and methods for treating cancer (e.g., PD-L1+ cancers). For example, methods and materials for using compositions (e.g., compositions containing a small bioactive S249/T252 phospho-mimicking polypeptide o...
|
|
WO/2019/165048A1 |
Disclosed herein are computer implemented methods of distinguishing ischemic stroke, hemorrhagic stroke, and stroke mimic by detecting circulating biomarkers in a subject. Also provided herein are systems, kits, and methods for the detec...
|
|
WO/2019/136531A1 |
Disclosed are proteinaceous molecules corresponding to an acetylation site and their use for inhibiting or reducing the nuclear localization of a nuclear localizable polypeptide, such as PD-1, PD-L1 and PD-L2. This invention also relates...
|
|
WO/2019/126186A1 |
Disclosed herein relates to immunotherapeutic compositions comprising immunotherapeutic peptides comprising neoepitopes, polynucleotides encoding the immunotherapeutic peptides, antigen presenting cells comprising the immunotherapeutic p...
|
|
WO/2019/096018A1 |
Provided herein are recombinant peptides useful for inhibiting the function of autophagy-related 8 (Atg8) proteins. The recombinant peptides can be used in the preparation of imaging agents for monitoring autophagy in a cell or subject a...
|
|
WO/2019/094938A2 |
The methods and compositions described herein address the need in the art by providing peptides and polypeptides comprising a growth factor binding domain. In some embodiments, the peptides have an amino acid sequence that is at least 80...
|
|
WO/2019/076856A1 |
The present invention relates to an adeno-associated virus (AAV), comprising an insertion of at least 6-8 amino acids between thepositions corresponding to position 87 and 588 of SEQ ID NO: 1. Also envisioned are AAVs of the present inve...
|
|
WO/2019/074870A1 |
The present disclosure relates compositions and methods for combinatorial drug discovery in nanoliter droplets. More particularly, the disclosure relates to novel synergistic agents that increase efficacy of antibiotic agents to treat ba...
|
|
WO/2019/055860A1 |
The invention relates to methods for treating cancers by targeting the elimination of selective activated immune cell populations in combination with checkpoint inhibitors. The cells may be targeted, for instance, using CLIP inhibitors a...
|
|
WO/2019/039179A1 |
Provided is a means for conveniently isolating exosome from a sample containing exosome. The present invention relates to a method for isolating exosome, the method comprising: a complex formation step for binding a specific peptide cont...
|
|
WO/2019/038789A1 |
The present disclosure provides a recombinant vector comprising BclB or BclA fused to a gene of interest encoding a fusion polypeptide for cell surface display of the fusion polypeptide. Also provided is a recombinant host cell comprisin...
|
|
WO/2019/036761A1 |
A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 5 peptide may ...
|
|
WO/2018/213320A1 |
Disclosed herein are conjugates including a fatty acid, a self-assembly domain, and a polypeptide having phase transition behavior. Further disclosed are methods of using the conjugates to treat disease, methods of delivering an agent, a...
|
|
WO/2018/208606A1 |
Disclosed herein is a CAR construct encoding an inhibitor of immunodeficiency virus fusion and human CD4 extracellular and transmembrane domains linked to a human CD3ζ signaling domain, and methods of making and using thereof to treat, ...
|
|
WO/2018/172065A1 |
The present invention relates to bacteriocins for control of Salmonella enterica (salmocins). The bacteriocins are derived from Salmonella. The salmocins can be expressed in plants and can be used in a method of preventing or reducing in...
|
|
WO/2018/140974A1 |
Disclosed herein are methods, reagents, and pharmaceutical compositions for modulating immune effector cell activation that does not requirean antigen-specific antibody. The IgG Fc region is shown herein to contain both a domain that bin...
|
|
WO/2018/132732A1 |
Disclosed herein are conjugates including a fatty acid, a self-assembly domain, and a polypeptide, where the conjugates have phase transition behavior. Further disclosed are methods of using the conjugates to treat disease, methods of de...
|
|
WO/2018/130834A1 |
The present invention relates to novel peptides derivable from the polypeptide chaperonin 60.1 and to their use in medicine, such as for the prevention and/or treatment of inflammatory conditions.
|
|
WO/2018/124425A1 |
The present invention relates to a novel peptide, a polynucleotide encoding the peptide, an expression vector comprising the polynucleotide, and a pharmaceutical composition, a quasi-drug composition, and a healthy functional food compos...
|
|
WO/2018/115602A1 |
The present invention relates to therapeutic peptides.
|
|
WO/2018/104922A1 |
The present invention relates to the efficient solid-phase synthesis of liraglutide represented by Formula-I. The present invention relates to an efficient process for the preparation of liraglutide by sequential coupling employing solid...
|
|
WO/2018/106470A1 |
The present invention is drawn to compositions and methods for improving transformation frequency. The compositions, synthetic selectable marker genes, are used in transformation methods and result in increased transformation frequency.
|
|
WO/2018/067291A1 |
Specifically, methods for patient stratification and selection of personalized peptide based treatments and vaccines are disclosed, including assays for identifying antigenic and immunogenic peptides involved in immune responses of mamma...
|
|
WO/2018/048806A1 |
The present invention provides compounds that are antagonists of CXCR4 and methods for using the same for treatment of a clinical condition associated with CXCR4 activation. In particular, compounds of the invention include cyclic peptid...
|
|
WO/2018/023028A1 |
Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with synucleinopathy and for measuring synucleinopathy progression or status. Test kits for diagnosis of an indiv...
|
|
WO/2018/005556A1 |
Provided are methods of identifying peptide epitopes of an antigen recognized by the non-classical major histocompatibility complex (MHC) molecule designated MHC-E. In some embodiments, the antigen is a tumor antigen, autoimmune antigen ...
|
|
WO/2017/190263A1 |
Provided are derivatives of a snake venom C fragment straight-chain polypeptide and a cyclic peptide related thereto, and a preparation method therefor. The derivatives comprise a parent peptide sequence as shown in formula I: R1-P1-Asp-...
|
|
WO/2017/192460A1 |
This disclosure relates to isotopically modified amino acids and their pharmaceutical or nutritional uses in stabilizing pharmaceutical protein-based formulations, proteins with long life span, and preventing or treating disease such as ...
|
|
WO/2017/188498A1 |
An antimicrobial peptide and an antimicrobial peptide composition containing the same, of the present invention, have remarkably higher antimicrobial activity against gram (+) and gram (-) strains than wild type LPcin-I, which has antimi...
|
|
WO/2017/176076A1 |
The present invention relates to a novel, translationally controlled tumor protein derived-protein transduction domain (TCTP-PTD) having the ability to penetrate the cell membrane, and to the use thereof. The TCTP-PTD peptide of the pr...
|
|
WO/2017/173321A1 |
The field of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer.
|
|
WO/2017/165617A1 |
Methods for assessing the efficacy of internally cross-linked p53 transactivation domain-based inhibitor peptides in the treatment of pediatric cancer and methods of using such peptides to treat pediatric cancer are provided.
|
|
WO/2017/158367A1 |
The present invention relates to novel peptides derived from Progesterone-associated endometrial protein (PAEP), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC...
|
